跳至主要内容
临床试验/NCT00084890
NCT00084890终止1 期

Weekly Docetaxel and Carboplatin in Patients With Recurrent Squamous Carcinoma of the Cervix: A Phase I/II Study

Wake Forest University Health Sciences2 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2003年11月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
终止
入组人数
15
试验地点
2
主要终点
Maximum tolerated dose of docetaxel

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining docetaxel with carboplatin may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of docetaxel when given together with carboplatin and to see how well they work in treating patients with recurrent stage IVB squamous cell carcinoma (cancer) of the cervix.

详细描述

OBJECTIVES:

Primary

  • Determine the maximum tolerated dose of docetaxel when administered with carboplatin in patients with recurrent stage IVB squamous cell carcinoma of the cervix.
  • Determine the response rate and time to progression in patients treated with this regimen.

Secondary

  • Determine the toxicity of this regimen in these patients.
  • Determine the quality of life of patients treated with this regimen.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Maximum tolerated dose of docetaxel

时间窗: 28 days

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Docetaxel and Carboplatin in Treating Patients With... | 临床试验